Dalton Pharma Services and Lonza jointly announce a
co-operation created to provide clients with geographically diversified,
fully integrated chemistry services from bench to commercial production
of active pharmaceutical ingredients.
In order to maximize productivity in an era demanding capital
efficiency, pharmaceutical development companies have been seeking
Chemistry Service Providers that can offer the right capabilities at the
right stage of the Drug Development Process. From Discovery through to
Commercial Production, supplier relationships are structured to ensure
quality and timeliness with a focus on good project management
principles and smooth transfers of technology at each critical phase.
“Our clients have been asking for this full spectrum of capabilities to fill an important need in our industry,” said Peter Pekos,
President and CEO of Dalton Pharma Services. “Over the past two decades
I have worked to adjust our service offering to meet the changing
requirements of my clients and today’s announcement is part of this
continuing evolution,” he continued. “In Lonza we have the ideal
partner: vastly experienced process R&D- and scale-up experts with
early clinical trial to large scale commercial cGMP and ISO
manufacturing at their sites in Switzerland and China.
Lonza has a reputation for high ethics, quality and environmental
standards which excellently matches with Dalton’s high standards.”
Stefan Stoffel, Head of Lonza Chemical
Custom Manufacturing, remarked, “We are very pleased to have established
and qualified Dalton Pharma Services as Lonza-trusted partner. Dalton
is a premium North American CRO in the areas of medicinal and early
stage chemistry, cGMP kg-lab manufacturing as well as formulation and
aseptic fill finish. Their services complement Lonza’s existing small
molecules capabilities and add the desired proximity to key customers in
the North American pharmaceutical market.”
